Therefore, taking into consideration the positive controls, our in silico molecular analysis identified darifenacin, an approved drug for the treatment of overactive bladder and urinary incontinence and an antagonist of the muscarinic M3 receptor, CHRM3 [41], with the ability to bind to CHI3L1, and thus with potential to have antitumor activity. This evidence concerns the gene CHRM3 and Urinary incontinence.